吉西他滨固定速率滴注与30min滴注治疗恶性肿瘤血液学毒性比较

目的]比较含吉西他滨固定速率（FDR）滴注方案和30min标准滴注方案治疗恶性肿瘤的血液学毒性。方法]25例经组织病理学或细胞学诊断的恶性肿瘤患者,采用吉西他滨单药或者含吉西他滨的联合方案化疗,随机分为固定速率静脉滴注（每分钟10mg/m2）（FDR组）或30min标准滴注（标准组）,每21d重复。每个周期结束后评价患者血液学毒性。结果]FDR组13例共完成28个周期化疗,标准组12例共完成32个周期化疗,所有患者均可评价血液学毒性。两组Ⅲ/Ⅳ度白细胞抑制有显著性差异（14.3%vs0,P=0.042）,两组Ⅲ/Ⅳ度中性粒细胞抑制、血小板抑制和血红蛋白抑制无明显差异（P〉0.05）。结论]吉西他滨固定速率滴注治疗恶性肿瘤的血液学毒性是可耐受的。

Hematologic Toxicity of Gemcitabine: A Comparison between Fixed-Dose Rate Infusion and 30-minute Infusion in the Treatment for Patients with Malignancy

Purpose] To compare the hematological toxicity of gemcitabine between fix dose rate(FDR) infusion and 30-minute infusion in the treatment for malignancy.Methods] Twenty-five cases with malignancy histopathologically or cytologically proven.All patients received chemotherapy with gemcitabine alone or combined with other chemotherapy agents.Patients were randomly divided into FDR infusion 10mg/(m2·min)](FDR group) or over 30 minutes infusion(standard group).The cycle was repeated every 21 days.Hematologic toxicity was evaluated at the end of each cycle.Results] A total of 28 cycles was completed in 13 patients with FDR group,and 32 cycles in 12 patients with standard group.All patients were evaluable for hematological toxicity.There was significantly different of leucopenia grade Ⅲ/Ⅳ between the 2 groups(14.3% vs 0,P<0.05),and no significant difference of neutropenia,thrombocytopenia and hemoglobin suppression grade Ⅲ/Ⅳ between the 2 groups(P>0.05).Conclusion] Hematologic toxicity of gemcitabine at a fix dose rate for malignancy is tolerable.